Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada — Clinical Trial Site

61 Registered trials

26 Currently recruiting

Organisation

Althaia Xarxa Assistencial Universitaria De Manresa Fundacio Privada

Location

Manresa, Spain

Identifier

ORG-100045540

Address

Dr Joan Soler 1-3, 08243, Spain

Departments

7004: Medical Oncology
Allergology
Anaesthesiology
cirugia
Departamento de oncologia
Gastroenterología
Haematology and Haemotherapy
Hematología
Hematology
Medica Oncology
Medical Oncology
Medicina interna
N/A
Neumology
Oncología
Oncology
Oncology department
Oncology Service
Ophtalmology
Pneumology
PSIQUIATRIA
Rheumatology
Servicio de Medicina Interna
Servicio de Oncología Médica
Servicio Oncologia Medica

Clinical trials at this site (61)

Search interface

An international study to evaluate the safety and effectiveness of enzalutamide plus leuprolide, enzalutamide alone, and leuprolide alone in… Ended

2024-513521-23-00 Prostate Cancer 5 2015-08-19
A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient… Ended

2024-517622-25-00 Patients with localized prostate cancer and high-risk f 5 2013-12-06
Ph 3b, BIC/FTC/TAF to DTG/3TC FDC, 96 Week switch, efficacy, safety, and tolerability study in ART-experienced older adults living with HIV … Ended

2022-503137-66-00 Human immunodeficiency virus (HIV) 5 2023-11-29
A Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) in Subjects with Fuchs Dystrophy Ended

2022-502643-35-00 Fuchs Endothelial Corneal Dystrophy 5 2023-08-09
A Study to Investigate the Safety and Effectiveness of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial … Ended

2024-511752-40-00 Fuchs Endothelial Corneal Dystrophy 5 2023-05-05
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan… Ended

2024-512227-36-00 Advanced solid tumors 9 2021-07-28
A phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously tr… Ended

2024-514611-98-00 PIK3CA mutated HER2+ advanced or relapsed breast cancer 5 2021-07-20
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local… Ended

2024-513870-23-00 Locally Advanced or Metastatic Unresectable Urothelial 5 2021-06-28
Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended

2023-510230-84-00 Severe asthma with an eosinophilic phenotype 5 2021-05-28
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 HR-positive/HER2-negative breast cancer 4 2021-05-04
First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended

2022-502124-52-00 Advanced epithelial ovarian cancer 5 2018-12-18
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13
A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nons… Ended

2024-515393-27-00 Nonsquamous non-small cell lung cancer 4